Get started
Author

Christopher Boston

Observed names: Boston, Christopher, C. Boston, CHRISTOPHER J. BOSTON
ORCID: 0000-0003-4403-2832
Observed ORCID: 0000-0003-4403-2832
OpenAlex ID: A5044570812
Selective inhibition of TGFβ1 activation overcomes primary resistance to checkpoint blockade therapy by altering tumor immune landscape
2020 · Constance J. Martin, Abhishek Datta, et al. · Science Translational Medicine · 224
Blocking extracellular activation of myostatin as a strategy for treating muscle wasting
2018 · M. Pirruccello-Straub, J. Jackson, et al. · Scientific Reports · 94
PDF
Design and Receptor Interactions of Obligate Dimeric Mutant of Chemokine Monocyte Chemoattractant Protein-1 (MCP-1)
2012 · Joshua H.Y. Tan, Meritxell Canals, et al. · Journal of Biological Chemistry · 45
PDF
302-OR: The Antimyostatin Antibody SRK-439 Promotes Healthy Body Composition in Combination with GLP-1RAs in a Mouse Model of Obesity
2024 · MELISSA A. FULHAM, CHRISTOPHER CHAPRON, et al. · Diabetes · 3
Abstract 4090: Defeating primary checkpoint resistance: SRTβ1-Ab3 is a first-in-class, fully human antibody that renders resistant tumors sensitive to anti-PD-1
2019 · Thomas Schürpf, Constance J. Martin, et al. · Cancer Research
Abstract 4090: Defeating primary checkpoint resistance: SRTβ1-Ab3 is a first-in-class, fully human antibody that renders resistant tumors sensitive to anti-PD-1
2019 · Thomas Schürpf, Constance J. Martin, et al. · Immunology
Works count: 7
Citation count: 367
H-index: 3
I10-index: 3
Year
Topic
Type